The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, ...

The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...

Based on the NCCN 1.2026 guidelines for the management of CSI seminoma, surveillance is strongly preferred for pT1-pT3 tumors ...

The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr.

An optimal PSA response, defined as ≤0.2 ng/mL, is achieved by approximately 51% of mHSPC patients 6–8 months after treatment ...

These data represent the first published dosimetry data for our investigational formulation of Lu-177 zadavotide guraxetan, with projected mean cumulative renal doses remaining low for a six-cycle ...

Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...

Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper ...

Evaluation of the Transition from Holmium:YAG to Pulsed Thulium:YAG for Laser Endoscopic Enucleation of the Prostate and the Effect on Procedural Performance. BPH - Benign Prostatic Enlargement March ...

ASCO 2025 Phase 1/2 Duravelo-1 study, nectin-4–targeting zelenectide pevedotin (BT8009), pembrolizumab, cisplatin-ineligible patients, locally advanced or metastatic urothelial cancer.

ASCO 2025, prostate cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), XALute Study, Xaluritamig, Cabazitaxel, Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy ...